<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193099</url>
  </required_header>
  <id_info>
    <org_study_id>C16-115</org_study_id>
    <secondary_id>2017-A00589-44</secondary_id>
    <nct_id>NCT03193099</nct_id>
  </id_info>
  <brief_title>Decoding Presymptomatic White Matter Changes in Huntington Disease</brief_title>
  <acronym>Win-HD</acronym>
  <official_title>Decoding Presymptomatic White Matter Changes in Huntington Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      WIN-HD is a monocentric longitudinal study comparing premanifest Huntingtin (HTT) mutation&#xD;
      carriers and non HTT mutation carriers to determine that white-matter atrophy occurs far&#xD;
      earlier than clinical onset in HD using Diffusion-weighted Nuclear Magnetic Resonance (N&#xD;
      spectroscopy (DWS) and Diffusion Tensor Imaging (DTI).&#xD;
&#xD;
      The investigators will recruit up to 20 premanifest HTT mutation carriers (15 completed) and&#xD;
      up to 20 non HTT mutation carriers (15 completed). It is important to have those 2&#xD;
      populations in order to compare our results and determine if there are significant&#xD;
      white-matter changes far from the onset of HD. Therefore, non HTT mutation carriers will be&#xD;
      age and gender matched to premanifest HTT mutation carriers.&#xD;
&#xD;
      In order to test the hypothesis, the study has 2 visits with a year interval.&#xD;
&#xD;
      This study is based on 4 principal criteria:&#xD;
&#xD;
        1. Imaging criteria&#xD;
&#xD;
        2. Clinical and neurological criteria&#xD;
&#xD;
        3. Psychological criteria&#xD;
&#xD;
        4. Behavioral criteria&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2017</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection by Diffusion-weighted spectroscopy of abnormal white matter changes prior to the onset of Huntington disease comparing HTT mutation carriers and non HTT mutation carriers over one year</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection by Diffusion-weighted spectroscopy of abnormal white matter changes over one year as an intersubject evolution</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection by Diffusion Tensor Imaging of abnormal white matter changes prior to the onset of Huntington disease comparing HTT mutation carriers and non HTT mutation carriers over one year.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection by Diffusion Tensor Imaging white matter changes over one year as an intersubject evolution.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of abnormal scores from psychological tests to assess possible early non motor changes and their intersubject evolution over one year.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of choice rates and time differences in the behavioral task comparing HTT mutation carriers and non HTT mutation carriers over one year.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of time differences in the behavioral task comparing HTT mutation carriers and non HTT mutation carriers over one year.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Huntington Disease</condition>
  <condition>White Matter Alterations</condition>
  <arm_group>
    <arm_group_label>Premanifest HTT mutation carriers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>non HTT mutation carriers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brain imaging</intervention_name>
    <description>Volume, DWS and DTI</description>
    <arm_group_label>Premanifest HTT mutation carriers</arm_group_label>
    <arm_group_label>non HTT mutation carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurological assessments</intervention_name>
    <description>UHDRS</description>
    <arm_group_label>Premanifest HTT mutation carriers</arm_group_label>
    <arm_group_label>non HTT mutation carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychological assessments</intervention_name>
    <description>STAI (Spielberger state and Trait Anxiety Inventory) A and B, BDI-II (Beck Depression Inventory), MINI (Mini-International Neuropsychiatric Interview) and MINI-SEA (mini Social cognitive and Emotional Assessment)</description>
    <arm_group_label>Premanifest HTT mutation carriers</arm_group_label>
    <arm_group_label>non HTT mutation carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioural assessments</intervention_name>
    <description>Computerized game</description>
    <arm_group_label>Premanifest HTT mutation carriers</arm_group_label>
    <arm_group_label>non HTT mutation carriers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For presymptomatic individuals:&#xD;
&#xD;
               -  Genetic test available with CAG (Cytosine-Adenine-Guanine) repeat length &gt; 36 in&#xD;
                  HTT gene&#xD;
&#xD;
               -  UHDRS score &lt;5&#xD;
&#xD;
               -  Burden score &lt;250&#xD;
&#xD;
          -  For controls:&#xD;
&#xD;
             - Genetic test available with CAG repeat length ≤ 36 in HTT gene&#xD;
&#xD;
          -  Common inclusion criteria for presymptomatic individuals and controls (age-matched and&#xD;
             gender-matched with presymptomatic individuals and but without any familial&#xD;
             relationship):&#xD;
&#xD;
               -  At least 18 years of age&#xD;
&#xD;
               -  Capacity to consent&#xD;
&#xD;
               -  Signature of the informed consent&#xD;
&#xD;
               -  Covered by social security&#xD;
&#xD;
               -  Ability to undergo MRI scanning&#xD;
&#xD;
        Non-Inclusion Criteria:&#xD;
&#xD;
          -  Under the age of 18 years of age&#xD;
&#xD;
          -  Contra-indications to MRI examination (metallic implant, pacemaker, artificial heart&#xD;
             valve, brain vascular malformation, aneurysm clips, exposed by metallic fragments,&#xD;
             artificial implants, peripheral or neuronal stimulator, insulin pump, intravenous&#xD;
             catheter, epilepsy, person with an history of seizure, metallic contraceptive device,&#xD;
             permanent eyelid make up, claustrophobia,…)&#xD;
&#xD;
          -  Unwillingness to be informed in case of abnormal MRI (with a significant medical&#xD;
             anomaly)&#xD;
&#xD;
          -  History of severe head injury&#xD;
&#xD;
          -  History of neurological disorder or presence of neurological disorder&#xD;
&#xD;
          -  Participation in a drug trial or exclusion period of another study&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Inability to understand information about the protocol&#xD;
&#xD;
          -  Person deprived of their liberty by judicial or administrative decision&#xD;
&#xD;
          -  Person under legal protection (legal guardianship, tutelage or maintenance of justice)&#xD;
&#xD;
          -  Person without any protection and unable to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra DURR, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brain and Spine Institute</name>
      <address>
        <city>Paris</city>
        <zip>750013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
    <mesh_term>Leukoaraiosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

